Home Tags Antibody-drug conjugate

Tag: antibody-drug conjugate

Annual World ADC Awards 2017: And the Winner is…

Earlier this month, the 8th World ADC meeting, held September 20 - 22, 2017 in San Diego and organized by Hanson Wade, offered a...

Registration of Antibody Drug Conjugates

Abstract      Antibody Drug Conjugates (ADC) are a rapidly expanding area of pharma company pipelines. They combine the targeting of an antibody with the potency...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Antibody-drug Conjugates: Intracellular Trafficking of New Anticancer Therapeutics

A new article, published by a team of writers including Muhammad Kalim, Jie Chen, and Shenghao Wang from the Department of Biochemistry and Genetics,...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

TAK-264 (MLN0264) in Previously Treated Patients with Advanced or Metastatic Pancreatic...

Authors: Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC,Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu...

PepTalk 2017: Antibody-drug Conjugates and the Promise of Innovation

ADC or antibody-drug conjugates have recently been at the forefront of cancer research, and according to the experts presenting their latest data during the...
IgG1 monoclonal antibody (immunoglobulin)

Strategies of Targeting the Extracellular Domain of RON Tyrosine Kinase Receptor...

Authors: Zarei O, Benvenuti S, Ustun-Alkan F, Hamzeh-Mivehroud M, Dastmalchi S. Title: Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer...

Targeting Breast Cancer with more Punch

To optimize current treatment and develop methods to more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells...

SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with...

Data presented today from an ongoing phase I clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate or ADC being developed by Seattle Genetics for the...

Piramal Expands Its Grangemouth ADC Manufacturing Base

Piramal Healthcare UK Ltd., has invested £2.0 million into Scotland to expand its manufacturing base at Grangemouth. The Scottish facility, approved by the U.S. Food...

Treatment Response to Mirvetuximab Soravtansine Found to be Substantially Greater in...

Findings with mirvetuximab soravtansine (also known as IMGN853 and M9346A-sulfo-SPDB-DM4), a novel folate receptor alpha (FRα)-targeting antibody-drug conjugate being developed by ImmunoGen, a clinical-stage...